← Human Trials & Peer-Reviewed Studies
Postpartum hyperprolactinemia and hyporesponsiveness of growth hormone (GH) to GH-releasing peptide.
Plain-language guide to PMID 9435424 (1998): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 10 women, hyperparathyroidism.
Key Facts
- PMID
- 9435424
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 1998
- Study type
- Randomized Controlled Trial
- Authors
- de Zegher F et al. (7 authors)
- DOI
- 10.1210/jcem.83.1.4483
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the context of hyperparathyroidism.
Human PRL and GH as well as their respective receptors have closely related origins.
Through paracrine mechanisms, PRL-secreting "pregnancy cells" may modulate the secretory function of somatotropes, which are known to express PRL receptors.
Who Took Part
According to the abstract, 10 women were involved.
By PubMed's age tags, the people studied were adults, women only.
How the Study Was Run
The researchers set it up as a randomized, placebo-controlled and crossover study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.
In the crossover set-up each of the women took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.
What Was Measured
PubMed files the paper under topics including Hormones, Human Growth Hormone, Hyperprolactinemia, Lactation, Oligopeptides, Postpartum Period and Prolactin.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 10 women in people with hyperparathyroidism.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1998 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, Hyperparathyroidism research.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
- Hyperparathyroidism research
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.